Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $15,526.44 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 4,386 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $3.54, for a total transaction of $15,526.44. Following the completion of the sale, the director directly owned 43,171 shares of the company’s stock, valued at $152,825.34. This trade represents a 9.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Up 9.5%

NASDAQ:RXRX traded up $0.33 during trading hours on Thursday, hitting $3.80. The stock had a trading volume of 38,573,526 shares, compared to its average volume of 17,309,813. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The business has a 50 day simple moving average of $3.29 and a two-hundred day simple moving average of $3.82. The company has a market cap of $2.01 billion, a PE ratio of -3.17 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. During the same quarter last year, the company earned ($0.50) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was down 56.8% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on RXRX. Bank of America lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Morgan Stanley raised their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. International Assets Investment Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $31,000. Integral Investment Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $39,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter valued at approximately $41,000. Finally, Allworth Financial LP grew its stake in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.